Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.
-
Burslem GM, Bondeson DP, Crews CM. Scaffold hopping enables direct access to more potent PROTACs with in vivo activity. Chem Commun (Camb). 2020 Jun 23; 56(50):6890-6892.
-
Park CS, Lewis AH, Chen TJ, Bridges CS, Shen Y, Suppipat K, Puppi M, Tomolonis JA, Pang PD, Mistretta TA, Ma L, Green MR, Rau R, Lacorazza HD. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. Blood. 2019 11 28; 134(22):1960-1972.
-
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 09 15; 79(18):4744-4753.
-
Ma L, Pak ML, Ou J, Yu J, St Louis P, Shan Y, Hutchinson L, Li S, Brehm MA, Zhu LJ, Green MR. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 2019 05 21; 116(21):10482-10487.
-
Vicente-Due?as C, Gonz?lez-Herrero I, Sehgal L, Garc?a-Ram?rez I, Rodr?guez-Hern?ndez G, Pintado B, Blanco O, Criado FJG, Cenador MBG, Green MR, S?nchez-Garc?a I. Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. Leukemia. 2019 01; 33(1):249-278.
-
Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proc Natl Acad Sci U S A. 2017 10 31; 114(44):11751-11756.
-
Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood. 2016 Apr 07; 127(14):1803-13.
-
Ma L, Roderick J, Kelliher MA, Green MR. High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML. Methods Mol Biol. 2016; 1465:159-73.
-
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014 Sep 03; 6(252):252ra121.
-
Zhang H, Li S. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell. 2013 Mar; 4(3):186-96.